ARX788 on FDA Fast Track for Advanced HER2-positive Breast Cancers
News
ARX788 has been given a fast track designation by the U.S. Food and Drug Administration as a monotherapy for patients with HER2-positive metastatic breast cancer previously treated with at least ... Read more